Literature DB >> 11020283

Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.

M Cushman1, M Jayaraman, J A Vroman, A K Fukunaga, B M Fox, G Kohlhagen, D Strumberg, Y Pommier.   

Abstract

In an attempt to design and synthesize potential anticancer agents acting by inhibition of topoisomerase I (top1), a new series of indenoisoquinolines was prepared and tested for cytotoxicity in human cancer cell cultures and for activity against top1. The synthesis relied on the condensation of substituted Schiff bases with homophthalic anhydrides to produce cis-3-aryl-4-carboxyisoquinolones that were cyclized to indenoisoquinolines in the presence of thionyl chloride. Both top1 inhibitory activity and cytotoxicity maximized in a single compound, 6-[3-(2-hydroxyethyl)aminopropyl]-5,6-dihydro-2,3-dimethoxy-8, 9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline hydrochloride (19a), which proved to be a very potent top1 inhibitor having a 110 nM mean graph midpoint (MGM) when tested for cytotoxicity in 55 human cancer cell cultures. A number of structurally related indenoisoquinolines were also obtained that had both potent cytotoxicity as well as top1 inhibitory activity. The key feature of the more potent compounds was the presence of an aminoalkyl side chain on the indenoisoquinoline nitrogen atom. The DNA cleavage patterns induced by top1 in the presence of the indenoisoquinolines were different from those seen with camptothecin. Some of the cleavage sites induced by the indenoisoquinolines were different from those seen with camptothecin, and conversely, camptothecin induced unique cleavage sites not apparent with the indenoisoquinolines. However, both camptothecin and the indenoisoquinolines also induced DNA cleavage sites that were the same in both series but varied in intensity. In addition, some of the DNA cleavages seen with the free base of 19a (compound 18c) in the presence of top1 were inhibited at higher drug concentrations, suggesting either a direct inhibition of the enzyme or an alternative mechanism involving DNA intercalation. Consistent with intercalation, compound 18c did unwind DNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020283     DOI: 10.1021/jm000029d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

1.  Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.

Authors:  Trung Xuan Nguyen; Andrew Morrell; Martin Conda-Sheridan; Christophe Marchand; Keli Agama; Alun Bermingham; Alun Bermingam; Andrew G Stephen; Adel Chergui; Alena Naumova; Robert Fisher; Barry R O'Keefe; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-04-26       Impact factor: 7.446

2.  Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-23       Impact factor: 7.446

3.  Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Authors:  Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-04-24       Impact factor: 7.446

4.  7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Sean DeGuire; Andrew Morrell; Keli Agama; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-08-08       Impact factor: 7.446

5.  Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.

Authors:  Wen-Lin Tang; Yu Zhang; De-Xuan Hu; Hui Yang; Qian Yu; Jian-Wen Chen; Keli Agama; Yves Pommier; Lin-Kun An
Journal:  Eur J Med Chem       Date:  2019-05-30       Impact factor: 6.514

Review 6.  Synthesis and Anticancer Properties of Functionalized 1,6-Naphthyridines.

Authors:  Mallu Lavanya; Chong Lin; Jincheng Mao; Dhakshanamurthy Thirumalai; Sreenath Reddy Aabaka; Xiaojiang Yang; Jinhua Mao; Zhiyu Huang; Jinzhou Zhao
Journal:  Top Curr Chem (Cham)       Date:  2021-02-24

7.  Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).

Authors:  Martin Conda-Sheridan; P V Narasimha Reddy; Andrew Morrell; Brooklyn T Cobb; Christophe Marchand; Keli Agama; Adel Chergui; Amélie Renaud; Andrew G Stephen; Lakshman K Bindu; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-12-21       Impact factor: 7.446

8.  3-(3-Bromo-benz-yl)isoquinolin-1(2H)-one.

Authors:  Farukh Iftakhar Ali; Tariq Mahmood Babar; Nasim Hasan Rama; Peter G Jones
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-12-04

9.  HPLC method development, validation, and impurity characterization of a potent antitumor indenoisoquinoline, LMP776 (NSC 725776).

Authors:  Jennie Wang; Mingtao Liu; Chun Yang; Xiaogang Wu; Euphemia Wang; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2016-02-27       Impact factor: 3.935

10.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.